If your doctor has determined that you are too sick for open-heart surgery, you may be eligible for a less-invasive treatment option that is now available. This procedure is called transcatheter mitral valve repair (TMVR) with MitraClip therapy.
Unlike surgery, the MitraClip procedure does not require opening the chest and temporarily stopping the heart. Instead, doctors access the mitral valve with a thin tube (called a catheter) that is guided through a vein in your leg to reach your heart.
The MitraClip device is a small clip that is attached to your mitral valve. It treats mitral regurgitation by allowing your mitral valve to close more completely, helping to restore normal blood flow through your heart.
As of July 2017, over 50,000 patients have been treated with the MitraClip device globally. In clinical studies in the U.S., more than 1,200 patients have undergone the MitraClip procedure, and over 900 of these patients have been followed for 1 year.
Clinical data from patients who underwent the MitraClip procedure demonstrate an immediate reduction of mitral regurgitation and a low hospital length of stay of 2.9 days. You should experience significant improvement in your symptoms of mitral regurgitation and quality of life soon after your procedure.
Low hospital length of stay
Improved quality of life
73% reduction in hospital visits for heart failure
Patients who were studied 1 year after the MitraClip procedure continued to experience improvement in their quality of life and ability to perform day-to-day tasks. They also had fewer visits to the hospital for complications due to heart failure.
The TMVR procedure is not right for everyone. In certain cases, the risks of the procedure may outweigh the benefits. See the important safety information below to review the risks of TMVR with the MitraClip procedure. You should also discuss with your doctor how the risks of the MitraClip procedure compare with other options that may be available to you.